Protocols at a Glance
PATIENT QUESTIONAIRRE
If you would like to be screened for a study, you can download the data-base questionnaire, complete and mail.
Debbie Slamowitz, RN
ACTG Office
Hoover Pavillion
211 Quarry Rd, N229
Palo Alto, CA 94304-5714
Questionairre.pdf
| Protocols | ACTG Protocols | Status |
|---|---|---|
| ACTG 5240 | Phase 2 study of HPV vaccine in HIV-1 Infected Females | Now Recruiting |
| ACTG 5241 | The Optimized Treatment that includes or Omits NRTIs (OPTIONS) Trial |
Now Recruiting |
| ACTG 5247 | Evaluation of therapy with ZOSTAVAX® for HIV-1-Infected Adults on ART with Conserved Immune Function | Pending |
NON ACTG Protocols Open at Stanford |
||
| BMS Impact | Phase IV, study to evaluate the I50L substitution among subjects experiencing virologic failure on a HAART regimen containing atazanavir (ATV) | Now recruiting |
| Gilead 183-0144 | A Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Ritonavir-Boosted Elvitegravir (EVG/r) Versus Raltegravir (RAL) Each Administered With a Background Regimen in HIV-1 Infected, Antiretroviral Treatment-Experienced Adults |
Now Recruiting |
| Victor E4 | Vicriviroc in Combination Treatment with an Optimized ART Regimen in HIV-Infected Treatment-Experienced Subjects | Now recruiting |